Cite

HARVARD Citation

    Rowe, M. et al. (2022). An analysis of survival in patients with castrate-resistant prostate cancer receiving enzalutamide with treatment breaks. Journal of clinical urology. pp. 257-263. [Online]. 
  
Back to record